GSK

GSK Chief Scientific Officer Hal Barron will depart in August to head San Francisco-based startup Altos Labs, the multinational announced Wednesday. He will be succeeded by Senior VP of Medicinal Science and Technology Tony Wood, a longtime Pfizer veteran.

The press release said Barron will remain on GSK’s board as he transitions to the $3 billion-funded biotech focused on cellular rejuvenation and reversing disease.

Barron’s move comes after less than five years on the job and…

The state of the fight: 

A booster dose of Bharat Biotech’s Covaxin increased neutralizing antibodies up to 265-fold.
  WHO added therapies from Eli Lilly and GSK/Vir to its list of recommended Covid-19 treatments.
  Novartis will pay over $162 million to in-license Molecular Partners’ ensovibep antiviral candidate.

 

AUTHORIZED VACCINES

Two doses of Pfizer/BioNTech’s vaccine reduced the risk of Covid-19 hospitalization by 94% among adolescents ages 12…

The state of the fight: 

India granted Biological E’s Corbevax—a low-cost, patent-free vaccine—its first regulatory authorization.
  A J&J booster was 85% effective against hospitalization in South Africa during the Omicron wave.
  India authorized molnupiravir but omitted the antiviral from its recommended clinical protocol on safety concerns.

 

AUTHORIZED VACCINES

 
Bharat Biotech’s Covaxin generated “superior antibody responses” in children…

Pfizer and BioNTech will jointly develop a third mRNA-based vaccine using Pfizer’s antigen technology and BioNTech’s mRNA platform—this time against shingles.

Under deal terms announced Wednesday, BioNTech will lock up $75 million in cash and an equity investment of $150 million from Pfizer. The German company could also earn milestone payments worth up to $200 million and a share of the profits, according to a joint press release. Pfizer, meanwhile, will get $25 million upfront from…

The state of the fight: 

Oral antivirals from Pfizer and Merck notched U.S. FDA authorizations.
  Earlier use of remdesivir cut the risk of death or hospitalization by 87% in a new study.
  The Novavax vaccine secured a second WHO Emergency Use Listing.

AUTHORIZED VACCINES  

The AstraZeneca/Oxford vaccine starts waning in protection against serious illness within three months of the second dose, according to cohort studies in Brazil and Scotland published…

ViiV has won U.S. FDA approval for Apretude, the first long-acting injectable for pre-exposure prophylaxis of HIV, the GSK subsidiary announced Monday.

The cabotegravir-based shot can be administered as few as six times per year after the first two 600-mg doses, per the press release. In clinical trials, Apretude offered 69%-90% lower incidences of HIV when compared to daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) tablets.

The FDA nod gives the injectable…

Mentions:

The state of the fight: 

WHO issued an Emergency Use Listing for Serum Institute of India’s version of Novavax’s vaccine.
  The U.S. CDC recommended mRNA-based vaccines over J&J’s.
  Data on the effectiveness of monoclonal antibody therapies against the Omicron variant began pouring in.

AUTHORIZED VACCINES  

A U.S. CDC advisory panel recommended mRNA-based vaccines over the J&J jab, citing blood clot side effects stemming from the single-dose…

The state of the fight: 

New studies supported heterologous primary regimens and heterologous boosters.
  Serum Institute of India is weighing slashing Covishield production by 50%.
  The U.S. FDA OK’d AstraZeneca’s Evusheld long-acting monoclonal antibody therapy as PrEP for certain groups.

 

AUTHORIZED VACCINES  

Mixing the AstraZeneca/Oxford or Pfizer/BioNTech vaccines with a second dose of Moderna’s shot generated non-inferior immune responses …

The state of the fight: 

A slew of vaccine manufacturers announced plans to tackle the Omicron variant.
  Aspen Pharmacare and J&J neared a deal that would let the South African manufacturer market its own version of the Janssen shot.
  Gavi’s board approved the alliance’s COVAX strategy for 2022.

AUTHORIZED VACCINES  


New research on the Pfizer/BioNTech shot affirmed its efficacy in younger people and its safety in older people.
 

GSK on Tuesday announced Phil Dormitzer as its new global head of vaccines R&D.

Dormitzer joins the multinational from Pfizer, where he was vice president and chief scientific officer for RNA and viral vaccines—and a key figure behind Pfizer's Covid-19 shot. He will report to GSK CSO Hal Barron starting this week.

FierceBiotech said the move is a boost to GSK after a "mini exodus" from the company that included losing former vaccine research chief Emmanuel Hanon to…